Form 4: NewAmsterdam Pharma Chief Scientific Officer Acquires 34,000 Restricted Stock Units

Johannes Jacob Pieter Kastelein, Chief Scientific Officer of NewAmsterdam Pharma, was granted 34,000 restricted stock units on January 7, 2025.

Summary

• Johannes Jacob Pieter Kastelein, the Chief Scientific Officer of NewAmsterdam Pharma Co N.V., received 34,000 restricted stock units (RSUs) on January 7, 2025.
• These RSUs represent a contingent right to receive one ordinary share each.
• The RSUs will vest in three equal installments, with one-third vesting on each of the first, second, and third anniversaries of the vesting start date.
• Vesting is contingent upon Mr. Kastelein's continued service with the company through each vesting date.
• The RSUs were granted without any consideration.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There is no indication of any negative sentiment.

Positives

• The grant of RSUs aligns the Chief Scientific Officer's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

The granting of restricted stock units is a common practice in the pharmaceutical industry to incentivize and retain key executives.

Comparison to Industry Standards

• The vesting schedule of one-third annually over three years is a standard practice for RSU grants in the biotech and pharmaceutical industries.
• Many companies in the sector use similar equity-based compensation to align executive interests with long-term shareholder value creation.
• Companies such as Regeneron, Amgen, and Gilead Sciences also use RSUs as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it incentivizes the Chief Scientific Officer to contribute to the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

restricted stock units, RSU, insider trading, executive compensation, stock options, NewAmsterdam Pharma, NAMS, Johannes Jacob Pieter Kastelein, Chief Scientific Officer